9 Biotechnology Stocks to Buy Now

9 Biotechnology Stocks to Buy Now

The grades of 9 Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

This is a strong week for Anacor Pharmaceuticals, Inc. (ANAC). The company’s rating climbs to B from the previous week’s C. Anacor Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing small-molecule therapeutics derived from boron chemistry platform. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ANAC stock.

This week, Medivation, Inc. (MDVN) pushes up from a C to a B rating. Medivation, Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. The company also gets A’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of MDVN stock.

Acceleron Pharma Inc (XLRN) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of XLRN stock.

The rating of Lexicon Pharmaceuticals, Inc. (LXRX) moves up this week, rising from a B to a A. Lexicon Pharmaceuticals, Inc. researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of LXRX stock.

Vital Therapies, Inc. (VTL) improves from a C to a B rating this week. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VTL stock.

ZIOPHARM Oncology, Inc. (ZIOP) boosts its rating from a C to a B this week. ZIOPHARM Oncology, Inc. is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

Exelixis, Inc. (EXEL) shows solid improvement this week. The company’s rating rises from a B to a A. Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of EXEL stock.

Vericel Corporation’s (VCEL) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of VCEL stock.

NanoViricides, Inc. (NNVC) earns a B this week, jumping up from last week’s grade of C. For more information, get Portfolio Grader’s complete analysis of NNVC stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/05/9-biotechnology-stocks-to-buy-now-3/.

©2019 InvestorPlace Media, LLC